TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by several foreign nations for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn. BRIUMVI® is a registered trademark of TG Therapeutics, Inc. read more

EMPLOYEE PARTICIPANTS: 31

TOTAL RATINGS: 639

CEO: Michael S. Weiss

HR or Marketing? Claim Your Free Employer Account

TG Therapeutics Awards

TG Therapeutics has not won any awards as of yet. However, based on 639 ratings and 31 participants, employees at TG Therapeutics are very satisfied with their work experience. The overall culture score, 80/100 or A, incorporates employee ratings based on their feedback on the Office Culture, eNPS, Happiness and more. Also, TG Therapeutics ranks in the top 10% of similar size companies and top 10% of companies on Comparably

Awards

Comparably Awards are provided yearly to top performing company cultures based on real feedback from their employees.

TG Therapeutics hasn't won any awards yet.

Top

10%

TG Therapeutics currently ranks in the Top 10% of similarly sized companies on Comparably

Top

10%

TG Therapeutics currently ranks in the Top 10% of nearby companies

1st

TG Therapeutics currently ranks 1st place versus 3 competitors

Help Your Company Win 2026 Awards